These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 4555308)

  • 1. [Advances in the treatment of parkinsonism].
    Dowzenko A
    Neurol Neurochir Pol; 1972; 6(2):275-80. PubMed ID: 4555308
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined treatment of parkinsonism with L-dopa and amantadine.
    Godwin-Austen RB; Frears CC; Bergmann S; Parkes JD; Knill-Jones RP
    Lancet; 1970 Aug; 2(7669):383-5. PubMed ID: 4194690
    [No Abstract]   [Full Text] [Related]  

  • 3. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1971 Aug; 26(8):61-70. PubMed ID: 5096462
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent advances in the treatment of Parkinsonism with drugs.
    Rinne UK
    Acta Neurol Scand Suppl; 1972; 51():59-103. PubMed ID: 4576076
    [No Abstract]   [Full Text] [Related]  

  • 5. [Parkinsonism. Therapeutic, pathophysiological, pharmacological and biochemical aspects].
    Dupont E
    Ugeskr Laeger; 1973 Jan; 135(3):116-22. PubMed ID: 4567942
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic uses and side effects of L-dopa.
    Boshes B
    Adv Intern Med; 1972; 18():219-49. PubMed ID: 4576081
    [No Abstract]   [Full Text] [Related]  

  • 7. [Long term treatment of a parkinsonism with l-dopa].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2111-3. PubMed ID: 4590069
    [No Abstract]   [Full Text] [Related]  

  • 8. Modification of Parkinsonism--chronic treatment with L-dopa.
    Cotzias GC; Papavasiliou PS; Gellene R
    N Engl J Med; 1969 Feb; 280(7):337-45. PubMed ID: 4178641
    [No Abstract]   [Full Text] [Related]  

  • 9. Levodopa and amantadine in the treatment of Parkinsonism.
    Critchley E
    Practitioner; 1972 Apr; 208(246):499-504. PubMed ID: 5031037
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of drugs in the treatment of parkinsonism.
    Nutr Rev; 1970 Jan; 28(1):7-9. PubMed ID: 4906659
    [No Abstract]   [Full Text] [Related]  

  • 11. Theoretical implications of the use of L-dopa in parkinsonism. A review.
    Klawans H; Ilahi MM; Shenker D
    Acta Neurol Scand; 1970; 46(4):409-41. PubMed ID: 4323341
    [No Abstract]   [Full Text] [Related]  

  • 12. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 13. [Long-term treatment of Parkinsonism with L-dopa].
    Presthus J; Holmsen R
    Tidsskr Nor Laegeforen; 1972 Nov; 92(33):2262-6. PubMed ID: 4630916
    [No Abstract]   [Full Text] [Related]  

  • 14. L-Dopa and Parkinsonism.
    Calne DB; Sandler M
    Nature; 1970 Apr; 226(5240):21-4. PubMed ID: 4907560
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinsonism.
    Med J Aust; 1970 Apr; 1(15):742-3. PubMed ID: 4317184
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of Parkinsonism with oral L-DOPA combined with a decarboxylase inhibitor (Ro IV 46.02)].
    Tissot R; Gaillard JM; Guggisberg M; Gauthier G; de Ajuriaguerra J
    Presse Med (1893); 1969 Apr; 77(17):619-22. PubMed ID: 5785081
    [No Abstract]   [Full Text] [Related]  

  • 17. L-dopa and amantadine for Parkinsonism.
    Drug Ther Bull; 1970 Aug; 8(17):65-7. PubMed ID: 5480244
    [No Abstract]   [Full Text] [Related]  

  • 18. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 19. Combined L-dopa and amantadine in Parkinsonism.
    Pollock M; Jorgensen PB
    Aust N Z J Med; 1972 Aug; 2(3):252-5. PubMed ID: 4564049
    [No Abstract]   [Full Text] [Related]  

  • 20. L-dopa and amantadine hydrochloride in Parkinson's disease.
    Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R
    Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.